other material
confidence high
sentiment positive
materiality 0.75
Nurix Therapeutics: NX-5948 achieves 69.2% ORR in Phase 1 CLL; pivotal trial planned for 2025
Nurix Therapeutics, Inc.
- Objective response rate of 69.2% in 26 evaluable CLL patients across 50-600 mg daily doses; responses deepened over time.
- Heavily pretreated population: median 4 prior therapies (96.8% BTKi, 90.3% BCL2i, 25.8% non-covalent BTKi).
- 43.3% had BTK mutations, 20% PLCG2 mutations, 46.7% TP53 mutations; CNS involvement in 2 patients responded.
- NX-5948 well tolerated; common adverse events: purpura/contusion, thrombocytopenia, neutropenia.
- Company plans to initiate pivotal, registration-directed trial(s) for NX-5948 in 2025.